These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regulation and modulation of antitumor immunity in pancreatic cancer. Leinwand J; Miller G Nat Immunol; 2020 Oct; 21(10):1152-1159. PubMed ID: 32807942 [TBL] [Abstract][Full Text] [Related]
3. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Steele CW; Karim SA; Leach JDG; Bailey P; Upstill-Goddard R; Rishi L; Foth M; Bryson S; McDaid K; Wilson Z; Eberlein C; Candido JB; Clarke M; Nixon C; Connelly J; Jamieson N; Carter CR; Balkwill F; Chang DK; Evans TRJ; Strathdee D; Biankin AV; Nibbs RJB; Barry ST; Sansom OJ; Morton JP Cancer Cell; 2016 Jun; 29(6):832-845. PubMed ID: 27265504 [TBL] [Abstract][Full Text] [Related]
4. Part II: Checkpoint inhibitors in cancer therapy. Daud AI Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974 [No Abstract] [Full Text] [Related]
5. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. Kimbara S; Kondo S World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267 [TBL] [Abstract][Full Text] [Related]
6. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722 [TBL] [Abstract][Full Text] [Related]
8. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma. Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673 [TBL] [Abstract][Full Text] [Related]
9. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint therapy for pancreatic cancer. Johansson H; Andersson R; Bauden M; Hammes S; Holdenrieder S; Ansari D World J Gastroenterol; 2016 Nov; 22(43):9457-9476. PubMed ID: 27920468 [TBL] [Abstract][Full Text] [Related]
17. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. Kieler M; Unseld M; Bianconi D; Prager G Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215 [TBL] [Abstract][Full Text] [Related]
19. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992 [TBL] [Abstract][Full Text] [Related]
20. New approaches tackle rising pancreatic cancer rates. Brower V J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25535299 [No Abstract] [Full Text] [Related] [Next] [New Search]